Aclaris Therapeutics (NASDAQ:ACRS) Issues Earnings Results, Beats Estimates By $0.07 EPS

Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) released its quarterly earnings results on Monday. The biotechnology company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.07, Briefing.com reports. The firm had revenue of $9.30 million for the quarter, compared to analysts’ expectations of $1.57 million. Aclaris Therapeutics had […]

Leave a Reply

Your email address will not be published.

Previous post Zoom Video Communications, Inc. (NASDAQ:ZM) Stock Position Lowered by Vectors Research Management LLC
Next post Lucid Motors Latest Financial Results Show They Lost Over $430K Per Each Vehicle Sold in Q3 2023